Role and mechanism of microglial activation in iron-induced selective and progressive dopaminergic neurodegeneration

Molecular Neurobiology

Volumn 49, Issue 3, 2014, Pages 1153-1165

  Zhang, Wei ^a,b,c   Yan, Zhao Fen ^a   Gao, Jun Hua ^a   Sun, Li ^a   Huang, Xi Yan ^a   Liu, Zhuo ^a   Yu, Shu Yang ^a   Cao, Chen Jie ^a   Zuo, Li Jun ^a   Chen, Ze Jie ^a   Hu, Yang ^a   Wang, Fang ^a   Hong, Jau Shyong ^d   Wang, Xiao Min ^b,e,f  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c Beijing Key Laboratory for Parkinson's Disease   (China)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e CAPITAL MEDICAL UNIVERSITY   (China)

^f BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Dopaminergic neurodegeneration; Iron; Mechanism; Microglial activation; Neuroinflammation; Parkinson's disease; nicotinamide adenine dinucleotide phosphate oxidase 2

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; CYBB PROTEIN, MOUSE; MEMBRANE PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; MICROGLIA; MICROGLIAL CELL CULTURE; NERVE CELL; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECTS; ENZYMOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE; NERVE DEGENERATION; PATHOLOGY; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; CELLS, CULTURED; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; IRON; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICROGLIA; NADPH OXIDASE; NERVE DEGENERATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84902548750     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8586-4     Document Type: Article

References (58)

1. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57-69. doi:10.1038/nrn2038 (Pubitemid 46011999)
2. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer 's disease brains. Neurology 38:1285-1291, PMID: 3399080
3. Zhang W, Wang T, Qin L, Gao HM, Wilson B, Ali SF et al (2004) Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J 18:589-591. doi:10.1096/fj.03-0983fje
4. Jung BD, Shin EJ, Nguyen XK, Jin CH, Bach JH, Park SJ et al (2010) Potentiation of methamphetamine neurotoxicity by intrastriatal lipopolysaccharide administration. Neurochem Int 56:229-244. doi:10.1016/j.neuint.2009.10.005
5. Gao HM, Hong JS, Zhang W, Liu B (2003) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci 23:1228-1236, PMID: 12598611 (Pubitemid 36258901)
6. Miller RL, Sun GY, Sun AY (2007) Cytotoxicity of paraquat in microglial cells: involvement of PKCdelta- and ERK1/2-dependent NADPH oxidase. Brain Res 1167:129-139. doi:10.1016/j.brainres.2007.06.046 (Pubitemid 47302435)
7. Zecca L, Zucca FA, Albertini A, Rizzio E, Fariello RG (2006) A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology 67:S8-S11. doi:10.1212/WNL.67.7-suppl-2.S8 (Pubitemid 44568828)
8. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML et al (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19:533-542. doi:10.1096/fj.04-2751com (Pubitemid 40471244)
9. Zhang W, Dallas S, Zhang D, Guo JP, Pang H, Wilson B et al (2007) Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 55:1178-1188. doi:10.1002/glia.20532 (Pubitemid 47204209)
10. Bernstein AI, Garrison SP, Zambetti GP, O'Malley KL (2011) 6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death. Mol Neurodegener 6:2. doi:10.1186/1750-1326-6-2
11. Cho Y, Son HJ, Kim EM, Choi JH, Kim ST, Ji IJ et al (2009) Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotox Res 16:361-371. doi:10.1007/s12640-009-9078-1
12. Levesque S, Wilson B, Gregoria V, Thorpe LB, Dallas S, Polikov VS et al (2010) Reactive microgliosis: extracellular micro-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 133:808-821. doi:10.1093/brain/awp333
13. Block ML, Wu X, Pei Z, Li G, Wang T, Qin L et al (2004) Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase. FASEB J 18:1618-1620. doi:10.1096/fj.04-1945fje (Pubitemid 39561652)
14. Arreguin S, Nelson P, Padway S, Shirazi M, Pierpont C (2009) Dopamine complexes of iron in the etiology and pathogenesis of Parkinson's disease. J Inorg Biochem 103:87-93. doi:10.1016/j.jinorgbio.2008.09.007
15. Berg D, Hochstrasser H (2006) Iron metabolism in Parkinsonian syndromes. Mov Disord 21:1299-1310. doi:10.1002/mds.21020 (Pubitemid 44613277)
16. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE et al (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114(Pt 4):1953-1975. doi:10.1093/brain/114.4.1953
17. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H (2009) Dietary fats cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism Relat Disord 15:47-52. doi:10.1016/j. parkreldis.2008.03.002
18. Barbeito AG, Garringer HJ, Baraibar MA, Gao X, Arredondo M, Nunez MT et al (2009) Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene. J Neurochem 109:1078. doi:10.1111/j.1471-4159.2009.06028.x
19. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT et al (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 57:176-179. doi:10.1002/ana.20369 (Pubitemid 40179854)
20. Riederer P, Rausch WD, Schmidt B, Kruzik P, Konradi C, Sofic E et al (1988) Biochemical fundamentals of Parkinson's disease. Mt Sinai J Med 55:21-28, PMID: 3279302 (Pubitemid 18047086)
21. Hare D, Ayton S, Bush A, Lei P (2013). A delicate balance: iron metabolism and diseases of the brain. Front Aging Neurosci. 5:34. doi: 10.3389/fnagi.2013.00034. eCollection: 2013.
22. Dexter DT, Carayon A, Vidailhet M, Ruberg M, Agid F, Agid Yet al (1990) Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 55:16-20. doi:10.1111/j.1471-4159.1990.tb08814.x
23. Werner CJ, Heyny-Von Haussen R, Mall G, Wolf S (2008) Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci 6:8. doi:10.1186/1477-5956-6-8
24. Zhang X, Dong F, Ren J, Driscoll MJ, Culver B (2005) High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp Neurol 191:318-325. doi:10.1016/j.expneurol.2004.10.011 (Pubitemid 40092875)
25. Kelleher P, Pacheco K, Newman LS (2000) Inorganic dust pneumonias: the metal-related parenchymal disorders. Environ Health Perspect 108(Suppl 4):685-696, PMID: 10931787
26. Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA et al (2011) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 19:63-72. doi:10.1007/s12640-009-9140-z
27. Aisen P, Enns C, Wessling-Resnick M (2001) Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol 33:940-959. doi:10.1016/S1357-2725(01) 00063-2
28. Moos T, Morgan EH (2004) The metabolism of neuronal iron and its pathogenic role in neurological disease: review. Ann N Y Acad Sci 1012:14-26. doi:10.1196/annals.1306.002 (Pubitemid 38453512)
29. Leitner DF, Connor JR (2012) Functional roles of transferrin in the brain. Biochim Biophys Acta 1820:393-402. doi:10.1016/j.bbagen.2011.10.016
30. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S et al (2005) The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1:191- 200. doi:10.1016/j.cmet.2005.01.003
31. Abboud S, Haile DJ (2000) A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 275:19906-19912. doi:10.1074/jbc.M000713200 (Pubitemid 30441595)
32. Dringen R, Bishop GM, Koeppe M, Dang TN, Robinson SR (2007) The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem Res 32:1884-1890. doi:10.1007/s11064-007-9375-0 (Pubitemid 47497889)
33. Lowe JS, Leigh N (2002). Disorders of movement and system degenerations. In Graham DI, Lantos PL, editors. Greenfield's Neuropathology. 7th ed. London: Arnold. 2: 325-430.
34. Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol 84:100-104, PMID: 1502878
35. Castellani RJ, Siedlak SL, Perry G, Smith MA (2000) Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol 100:111-114. doi:10.1007/s004010050001 (Pubitemid 30456131)
36. Lv Z, Jiang H, Xu H, Song N, Xie J (2011) Increased iron levels correlate with the selective nigral dopaminergic neuron degeneration in Parkinson's disease. J Neural Transm 118:361-369. doi:10.1007/s00702-010-0434-3
37. Chew KC, Ang ET, Tai YK, Tsang F, Lo SQ, Ong E et al (2011) Enhanced autophagy from chronic toxicity of iron and mutant A53T alpha-synuclein: implications for neuronal cell death in Parkinson disease. J Biol Chem 286:33380-33389. doi:10.1074/jbc.M111.268409
38. Wypijewska A, Galazka-Friedman J, Bauminger ER, Wszolek ZK, Schweitzer KJ, Dickson DW et al (2010) Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism Relat Disord 16:329-333. doi:10.1016/j.parkreldis.2010.02.007
39. Dutta G, Zhang P, Liu B (2008) The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 22:453-464. doi:10.1111/j.1472-8206.2008.00616.x
40. Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510-518. doi:10.1016/j.nbd.2009.11.004
41. Infanger DW, Sharma RV, Davisson RL (2006) NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal 8:1583-1596. doi:10.1089/ars.2006.8.1583 (Pubitemid 44726333)
42. Stewart VC, Heales SJ (2003) Nitric oxide-induced mitochondrial dysfunction: implications for neurodegeneration. Free Radic Biol Med 34:287-303. doi:10.1016/S0891-5849(02)01327-8 (Pubitemid 36120745)
43. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS et al (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55:453-462. doi:10.1002/glia.20467 (Pubitemid 46383175)
44. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson's disease. Mov Disord 23:474-483. doi:10.1002/mds.21751
45. Ouchi Y, Yagi S, Yokokura M, Sakamoto M (2009) Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 15(Suppl 3):S200-S204. doi:10.1016/S1353-8020(09)70814-4
46. Block ML (2008) NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci 9(Suppl 2):S8. doi:10.1186/1471-2202-9-S2-S8
47. Tammariello SP, Quinn MT, Estus S (2000) NADPH oxidase contributes directly to oxidative stress and apoptosis in nerve growth factor-deprived sympathetic neurons. J Neurosci 20:RC53, PMID: 10627630
48. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B et al (2004) NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 279:1415-1421. doi:10.1074/jbc.M307657200 (Pubitemid 38082669)
49. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, de Yebenes JG, Mena MA (2006) Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97:934-946. doi:10.1111/j.1471-4159.2006.03777.x
50. Sorce S, Krause KH (2009) NOX enzymes in the central nervous system: from signaling to disease. Antioxid Redox Signal 11:2481-2504. doi:10.1089/ARS.2009. 2578
51. Miller RL, James-Kracke M, Sun GY, Sun AY (2009) Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34:55-65. doi:10.1007/s11064-008-9656-2
52. Zhao X, Xu B, Bhattacharjee A, Oldfield CM, Wientjes FB, Feldman GM et al (2005) Protein kinase Cdelta regulates p67phox phosphorylation in human monocytes. J Leukoc Biol 77:414-420. doi:10.1189/jlb.0504284 (Pubitemid 40289572)
53. Bey EA, Xu B, Bhattacharjee A, Oldfield CM, Zhao X, Li Q et al (2004) Protein kinase C delta is required for p47phox phosphorylation and translocation in activated human monocytes. J Immunol 173:5730-5738, PMID: 15494525 (Pubitemid 39392162)
54. Min KJ, Pyo HK, Yang MS, Ji KA, Jou I, Joe EH (2004) Gangliosides activate microglia via protein kinase C and NADPH oxidase. Glia 48:197-206. doi:10.1002/glia.20069 (Pubitemid 39545935)
55. Murphy LO, Blenis J (2006)MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31:268-275. doi:10.1016/j.tibs.2006.03.009 (Pubitemid 43674354)
56. Bardwell L (2006) Mechanisms of MAPK signalling specificity. Biochem Soc Trans 34:837-841. doi:10.1042/BST0340837
57. Flohe L, Brigelius-Flohe R, Saliou C, Traber MG, Packer L (1997) Redox regulation of NF-kappa B activation. Free Radic Biol Med 22:1115-1126. doi:10.1016/S0891-5849(96)00501-1 (Pubitemid 27084148)
58. Yang S, Yang J, Yang Z, Chen P, Fraser A, Zhang W et al (2006) Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress. J Pharmacol Exp Ther 319:595-603. doi:10.1124/jpet.106.102236